Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

HC Wainwright & Co. Downgrades TCR2 Therapeutics to Neutral

HC Wainwright & Co. analyst Robert Burns downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Neutral.
byBenzinga Newsdesk
March 7, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

HC Wainwright & Co. analyst Robert Burns downgrades TCR2 Therapeutics (NASDAQ:TCRR) from Buy to Neutral.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

5 Value Stocks In The Communication Services Sector

By Benzinga Insights
September 12, 10:52 AM
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

ADTH